Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti

SOLANA BEACH, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
May 15, 2017 16:05 ET | Source: Evoke Pharma

Evoke Pharma Reports First Quarter 2017 Results

Confirmed FDA acceptability of comparative exposure pharmacokinetic (PK) study design and agreement on related CMC data package elements for Gimoti™ new drug application (NDA)Partnered with Spaulding...
May 10, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017

SOLANA BEACH, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
May 01, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma Schedules Conference Call and Webcast for First Quarter 2017 Financial Results

SOLANA BEACH, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that...
April 18, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma Announces Collaboration with Spaulding Clinical Research for the Gimoti Comparative Exposure Pharmacokinetic Trial

SOLANA BEACH, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
April 04, 2017 08:30 ET | Source: Evoke Pharma

Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma’s Proposed Comparative Exposure PK Trial for Gimoti NDA

SOLANA BEACH, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 21, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma’s Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017

SOLANA BEACH, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 15, 2017 16:05 ET | Source: Evoke Pharma

Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results

SOLANA BEACH, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced its...
March 07, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results

SOLANA BEACH, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today...
March 06, 2017 08:30 ET | Source: Evoke Pharma

Evoke Pharma Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

SOLANA BEACH, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today...